Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease
Journal of Internal Medicine · 2025-01 · 297 (1) · 47-59
DOI: 10.1111/joim.20032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, online erschienen am 19.11.2024. Verfasst von Osman Ahmed und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Center for Molecular Medicine, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Membrane Proteins, Lipase, Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk fellowship and Stiftelsen Professor Nanna Svartz fond, Progetti di Rilevante Interesse Nazionale, Ricerca Finalizzata, Ministry of Health.
Abstract (Originalsprache)
Background and objectives Statins are used for metabolic dysfunction‐associated steatotic liver disease (MASLD) (NAFLD) treatment, but their role in this context is unclear. Genetic variants of patatin‐like phospholipase domain containing 3 ( PNPLA3 ) are associated with MASLD susceptibility and statin treatment efficacy. Access to liver biopsies before established MASLD is limited, and statins and PNPLA3 in early liver steatosis are thus difficult to study.
Methods
Liver biopsies were collected from 261 patients without known liver disease at surgery and stratified based on statin use and criteria for the metabolic syndrome (MS). Genotypes and transcript levels were measured using Illumina and Affymetrix arrays, and metabolic and lipoprotein profiles by clinical assays. Statin effects on PNPLA3, de novo lipogenesis (DNL), and lipid accumulation were further studied in vitro.
Results
The PNPLA3 I148M genetic variant was associated with significantly lower hepatic levels of cholesterol synthesis‐associated transcripts. Patients with MS had significantly higher hepatic levels of MASLD and lipogenesis‐associated transcripts than non‐MS patients. Patients with MS on statin therapy had significantly higher hepatic levels of PNPLA3 , acetyl‐CoA carboxylase alpha, and ATP citrate lyase, and statin use was associated with higher plasma fasting glucose, insulin, and HbA1c. Exposure of hepatocyte‐like HepG2 cells to atorvastatin promoted intracellular accumulation of triglycerides and lipogenesis‐associated transcripts. Atorvastatin‐exposure of HepG2, sterol O ‐acyltransferase (SOAT) 2 ‐only‐HepG2, primary human hepatic stellate, and hepatic stellate cell‐like LX2 cells significantly increased levels of PNPLA3 and SREBF2‐target genes, whereas knockdown of SREBF2 attenuated this effect.
Conclusions
Collectively, these observations suggest statin‐associated regulation of PNPLA3 and DNL in liver. The potential interaction between PNPLA3 genotype and metabolic status should be considered in future studies in the context of statin therapy for MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Center for Molecular Medicine, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
- Cardiovascular Research Theme, Bioclinicum J8, Karolinska University Hospital, Solna, Sweden.
- Department of Biochemistry, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
- Cardio Metabolic Unit, Department of Laboratory Medicine, and Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Medicine Unit of Endocrinology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden.
- Department of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, Milan, Italy.
ORCID-Profile: Osman Ahmed, Peter Saliba-Gustafsson, Matteo Pedrelli, Paolo Parini, Per Eriksson
Förderung
- Novo Nordisk fellowship and Stiftelsen Professor Nanna Svartz fond
- Progetti di Rilevante Interesse Nazionale
- Ricerca Finalizzata, Ministry of Health
- PNRR Missione 4
- PNRR Missione 6
- EUROPEAID
- Swedish Research Council
- Swedish Heart-Lung Foundation
Zitieren
APA
Ahmed, O., Shavva, V. S., Tarnawski, L., Dai, W., Borg, F., Olofsson, V. V., Liu, T., Saliba-Gustafsson, P., Simini, C., Pedrelli, M., Bergman, O., Norata, G. D., Parini, P., Franco-Cereceda, A., Eriksson, P., Malin, S. G., Björck, H. M., & Olofsson, P. S. (2025). Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease. Journal of Internal Medicine, 297(1), 47-59. https://doi.org/10.1111/joim.20032
Vancouver
Ahmed O, Shavva VS, Tarnawski L, Dai W, Borg F, Olofsson VV, et al. Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease. Journal of Internal Medicine. 2025;297(1):47-59. doi:10.1111/joim.20032
BibTeX
@article{Ahmed2025,
author = {Ahmed, Osman and Shavva, Vladimir S and Tarnawski, Laura and Dai, Wanmin and Borg, Filip and Olofsson, Viggo V and Liu, Ting and Saliba-Gustafsson, Peter and Simini, Christian and Pedrelli, Matteo and Bergman, Otto and Norata, Giuseppe Danilo and Parini, Paolo and Franco-Cereceda, Anders and Eriksson, Per and Malin, Stephen G and Björck, Hanna M and Olofsson, Peder S},
title = {Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease},
journal = {Journal of Internal Medicine},
year = {2025},
volume = {297},
number = {1},
pages = {47--59},
doi = {10.1111/joim.20032}
}
EUVIMED